|

Actinium Ac 225-DOTA-Daratumumab Clinical Trials

2 actively recruiting trials across 1 location

Also known as: 225Ac-DOTA-Daratumumab, 225Ac-DOTA-Daratumumab; [225Ac]-DOTA-Daratumumab, [225Ac]-DOTA-Daratumumab

Pipeline

Phase 1: 2

Top Sponsors

  • City of Hope Medical Center2

Indications

  • Cancer2
  • Refractory Plasma Cell Myeloma1
  • Recurrent Plasma Cell Myeloma1
  • Myelodysplastic Syndrome1
  • Acute Myeloid Leukemia1

Duarte, California2 trials

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

City of Hope Medical Center

Phase 1
Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

City of Hope Medical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.